secwatch.observer — SEC 8-K summary
======================================

Issuer:     Keros Therapeutics, Inc. (KROS)
CIK:        0001664710
Form:       8-K
Filed at:   2026-06-03T20:01:21+00:00
Accession:  0001664710-26-000034
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Keros Therapeutics announces stockholder votes at 2026 annual meeting
---------------------------------------------------------------------

- Elected Jean-Jacques Bienaimé and Charles Newton as directors with 10,093,559 and 14,716,598 votes for, respectively.
- Ratified Deloitte & Touche LLP as independent auditor for FY 2026 (16,708,279 for, 783,953 against).
- Advisory vote on executive compensation approved (14,273,625 for, 974,049 against).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1664710/000166471026000034/0001664710-26-000034-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1664710/000166471026000034/kros-20260603.htm
  HTML page:      https://secwatch.observer/filing/0001664710-26-000034

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer